Top

memo - Magazine of European Medical Oncology

Published in:

13-10-2020 | Chronic Lymphocytic Leukemia | original report

WNT3 and LEF1 as markers for diagnosis and survival prediction in chronic lymphocytic leukemia patients

Authors: Manal Atef, Layla M. Saleh, MD/PhD, Noha Eisa, Sameh Shamaa

Published in: memo - Magazine of European Medical Oncology | Issue 4/2023

Summary

Background

The Wnt pathway is aberrantly activated in chronic lymphocytic leukemia (CLL) and contributes to the antiapoptotic and mitogenic characteristics of CLL cells. Lymphoid enhancer-binding factor‑1 (LEF1) acts as a mediator and key transcription factor of the Wnt/β-catenin pathway. LEF1 helps to regulate important genes involved in tumor cell death mechanisms.

Objective

To analyze the expression levels of Wnt signaling pathway member (WNT3) and its key mediator LEF1 in Egyptian CLL patients and to detect the potential use of these genes as markers of CLL outcome.

Methods

We quantified the expression levels of Wnt3 and LEF1 in peripheral blood mononuclear cells of 30 untreated CLL and 19 healthy controls by qRT-PCR (quantitative real time polymerase chain reaction).

Results

Our study demonstrated significant upregulation of both Wnt3 and LEF1 in CLL (P < 0.0001). WNT3 and LEF1 were significantly decreased in CLL patients with ECOG performance 2 and 3 than those with 0 and 1 (p = 0.023 and 0.007, respectively). CLL patients with 17p deletion express significantly low LEF1 (p = 0.033). Low levels of WNT3 and LEF1 expression indicated a shorter overall survival (P = 0.007, 0.005, respectively). The predictive power of WNT3 and LEF1 expression showed good discrimination of CLL patients from controls (AUC >0.9).

Conclusion

Upregulation of WNT3 and LEF1 could be used as helpful and specific markers to distinguish our CLL patients. Low WNT3 and LEF1 expression is associated with shortened survival in CLL patients. These results indicate that WNT3 and LEF1 represent an attractive therapeutic target for future therapies in Egyptian CLL patients.

Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest. 2005;115:755–64. https://doi.org/10.1172/JCI23409.CrossRefPubMedPubMedCentral

Hallek M, Information CME. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. Am J Hematol. 2015;90:446–60. https://doi.org/10.1002/ajh.00046.CrossRefPubMed

Jelinek DF, Tschumper RC, Stolovitzky GA, Iturria SJ, Tu Y, Lepre J, et al. Identification of a global gene expression signature of B‑chronic lymphocytic leukemia. Mol Cancer Res. 2003;1:346–61.PubMed

Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194:1639–47.CrossRefPubMedPubMedCentral

Memarian A, Hojjat-Farsangi M, Asgarian-Omran H, Younesi V, Jeddi-Tehrani M, Sharifian RA, et al. Variation in WNT genes expression in different subtypes of chronic lymphocytic leukemia. Leuk Lymphoma. 2009;50:2061–70. https://doi.org/10.3109/10428190903331082.CrossRefPubMed

Wang L, Shalek AK, Lawrence M, Ding R, Gaublomme JT, Pochet N, et al. Somatic mutation as a mechanism of Wnt/beta-catenin pathway activation in CLL. Blood. 2014;124:1089–98. https://doi.org/10.1182/blood-2014-01-552067.CrossRefPubMedPubMedCentral

Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer. 2010;10:37–50. https://doi.org/10.1038/nrc2764.CrossRefPubMed

Gutierrez AJ, Tschumper RC, Wu X, Shanafelt TD, Eckel-Passow J, Huddleston PM 3rd, et al. LEF‑1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B‑cell lymphocytosis. Blood. 2010;116:2975–83. https://doi.org/10.1182/blood-2010-02-269878.CrossRefPubMedPubMedCentral

Poppova L, Janovska P, Plevova K, Radova L, Plesingerova H, Borsky M, et al. Decreased WNT3 expression in chronic lymphocytic leukaemia is a hallmark of disease progression and identifies patients with worse prognosis in the subgroup with mutated IGHV. Br J Haematol. 2016;175:851–9. https://doi.org/10.1111/bjh.14312.CrossRefPubMed

10.

MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17:9–26. https://doi.org/10.1016/j.devcel.2009.06.016.CrossRefPubMedPubMedCentral

11.

Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005;434:843–50. https://doi.org/10.1038/nature03319.CrossRefPubMed

12.

Gandhirajan RK, Staib PA, Minke K, Gehrke I, Plickert G, Schlösser A, et al. Small molecule inhibitors of Wnt/beta-catenin/lef‑1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo. Neoplasia. 2010;12:326–35. https://doi.org/10.1593/neo.91972.CrossRefPubMedPubMedCentral

13.

Menter T, Dirnhofer S, Tzankov A. LEF1: a highly speci fi c marker for the diagnosis of chronic lymphocytic B cell leukaemia/small lymphocytic B cell lymphoma. J Clin Pathol. 2015;68(6):473–8. https://doi.org/10.1136/jclinpath-2015-202862.CrossRefPubMed

14.

Wu W, Zhu H, Fu Y, Shen W, Miao K, Hong M, et al. High LEF1 expression predicts adverse prognosis in chronic lymphocytic leukemia and may be targeted by ethacrynic acid. Oncotarget. 2016;7:21631–43. https://doi.org/10.18632/oncotarget.7795.CrossRefPubMedPubMedCentral

15.

Skokowa J, Welte K. LEF‑1 is a decisive transcription factor in neutrophil granulopoiesis. Ann N Y Acad Sci. 2007;1106:143–51. https://doi.org/10.1196/annals.1392.012.CrossRefPubMed

16.

Reya T, O’Riordan M, Okamura R, Devaney E, Willert K, Nusse R, et al. Wnt signaling regulates B lymphocyte proliferation through a LEF‑1 dependent mechanism. Immunity. 2000;13:15–24. https://doi.org/10.1016/s1074-7613(00)00004-2.CrossRefPubMed

17.

Metzeler KH, Heilmeier B, Edmaier KE, Rawat VPS, Dufour A, Dohner K, et al. High expression of lymphoid enhancer-binding factor‑1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia. Blood. 2012;120:2118–26. https://doi.org/10.1182/blood-2012-02-411827.CrossRefPubMed

18.

Elbaiomy MA, Aref S, El Zaafarany M, Atwa S, Akl T, El-Beshbishi W, et al. Prognostic impact of lymphoid enhancer factor 1 expression and serum Galectin.3 in Egyptian AML patients. Adv Hematol. 2019;2019:2352919. https://doi.org/10.1155/2019/2352919.CrossRefPubMedPubMedCentral

19.

Aly RM, Yousef AB. Prognostic significance of lymphoid enhancer-binding factor‑1 expression in egyptian adult B‑acute lymphocytic leukemia patients. Turk J Haematol. 2015;32:15–20. https://doi.org/10.4274/tjh.2013.0140.CrossRefPubMedPubMedCentral

20.

Kuhnl A, Gokbuget N, Kaiser M, Schlee C, Stroux A, Burmeister T, et al. Overexpression of LEF1 predicts unfavorable outcome in adult patients with B‑precursor acute lymphoblastic leukemia. Blood. 2011;118:6362–7. https://doi.org/10.1182/blood-2011-04-350850.CrossRefPubMed

21.

Gutierrez A, Sanda T, Ma W, Zhang J, Grebliunaite R, Dahlberg S, et al. Inactivation of LEF1 in T‑cell acute lymphoblastic leukemia. Blood. 2010;115:2845–51. https://doi.org/10.1182/blood-2009-07-234377.CrossRefPubMedPubMedCentral

22.

Erdfelder F, Hertweck M, Filipovich A, Uhrmacher S, Kreuzer KA. High lymphoid enhancer-binding factor expression is associated with disease progression and poor prognosis in chronic lymphocytic leukemia. Hematol Rep. 2010;2:24–7. https://doi.org/10.4081/hr.2010.e3.CrossRef

23.

Spaulding C, Reschly EJ, Zagort DE, Yashiro-Ohtani Y, Beverly LJ, Capobianco A, et al. Notch1 co-opts lymphoid enhancer factor 1 for survival of murine T‑cell lymphomas. Blood. 2007;110:2650–8. https://doi.org/10.1182/blood-2007-04-084202.CrossRefPubMed

24.

McCarthy BA, Yancopoulos S, Tipping M, Yan X‑J, Wang XP, Bennett F, et al. A seven-gene expression panel distinguishing clonal expansions of pre-leukemic and chronic lymphocytic leukemia B cells from normal B lymphocytes. Immunol Res. 2015;63:90–100. https://doi.org/10.1007/s12026-015-8688-3.CrossRefPubMed

25.

Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, Leoni LM, et al. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2004;101:3118–23. https://doi.org/10.1073/pnas.0308648100.CrossRefPubMedPubMedCentral

26.

Lu D, Liu JX, Endo T, Zhou H, Yao S, Willert K, et al. Ethacrynic acid exhibits selective toxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/β-catenin pathway. PLoS One. 2009;4(12):e8294. https://doi.org/10.1371/journal.pone.0008294.CrossRefPubMedPubMedCentral

27.

Thanendrarajan S, Kim Y, Schmidt-Wolf IGH. Understanding and targeting the Wnt/β-catenin signaling pathway in chronic leukemia. Leuk Res Treatment. 2011;2011:1–7. https://doi.org/10.4061/2011/329572.CrossRef

28.

Petrini M, Conte A, Caracciolo F, Sabbatini A, Grassi B, Ronca G. Reversing of chlorambucil resistance by ethacrynic acid in a B-CLL patient. Br J Haematol. 1993;85:409–10. https://doi.org/10.1111/j.1365-2141.1993.tb03187.x.CrossRefPubMed

29.

Lu D, Choi MY, Yu J, Castro JE, Kipps TJ, Carson DA. Salinomycin inhibits wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A. 2011;108:13253–7. https://doi.org/10.1073/pnas.1110431108.CrossRefPubMedPubMedCentral

30.

Razavi R, Gehrke I, Gandhirajan RK, Poll-Wolbeck SJ, Hallek M, Kreuzer KA. Nitric oxide-donating acetylsalicylic acid induces apoptosis in chronic lymphocytic leukemia cells and shows strong antitumor efficacy in vivo. Clin Cancer Res. 2011;17:286–93. https://doi.org/10.1158/1078-0432.CCR-10-1030.CrossRefPubMed

Title: WNT3 and LEF1 as markers for diagnosis and survival prediction in chronic lymphocytic leukemia patients
Authors: Manal Atef
Layla M. Saleh, MD/PhD
Noha Eisa
Sameh Shamaa
Publication date: 13-10-2020
Publisher: Springer Vienna
Keywords: Chronic Lymphocytic Leukemia
Polymerase Chain Reaction
Published in: memo - Magazine of European Medical Oncology / Issue 4/2023
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-020-00651-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Summary

Background

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2023

Management of malignant hypercalcemia in cancer patients—a short review

ASCO update—hepatocellular carcinoma and cholangiocellular carcinoma

Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma

Editorial

ASCO 2023—partnering with patients: the cornerstone of cancer care and research

Prostate cancer special—part 1

Keynote webinar | Spotlight on antibody–drug conjugates in cancer